Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Mary J. Fidler, MD, considers whether lurbinectedin may improve outcomes in SCLC

Dr. Fidler, Associate Professor, Department of Internal Medicine, Division of Hematology, Oncology & Cell Therapy, Rush Medical College, Rush University Medical Center, considers whether lurbinectedin may improve outcomes for previously treated small-cell lung cancer (SCLC) patients

Tags: Lung (includes NSCLC, SCLC, Mesothelioma)

Published: 05 April 2021

Recent Videos: Lung (includes NSCLC, SCLC, Mesothelioma)

video

Mary J. Fidler, MD, considers whether lurbinectedin may improve outcomes in SCLC

Dr. Fidler, Associate Professor, Department of Internal Medicine, Division of Hematology, Oncology & Cell Therapy, Rush Medical College, Rush University ...

video

Mary J. Fidler, MD, on combination lurbinectedin & checkpoint inhibitors in the treatment of SCLC

Dr. Fidler, Associate Professor, Department of Internal Medicine, Division of Hematology, Oncology & Cell Therapy, Rush Medical College, Rush University ...

video

Mary J. Fidler, MD, regarding the role of trilaciclib as a supportive care agent for SCLC patients

Dr. Fidler, Associate Professor, Department of Internal Medicine, Division of Hematology, Oncology & Cell Therapy, Rush Medical College, Rush University ...

video

Mary J. Fidler, MD, elaborates on what early clinical trials have told us about sotorasib

Dr. Fidler, Associate Professor, Department of Internal Medicine, Division of Hematology, Oncology & Cell Therapy, Rush Medical College, Rush University ...

video

Mary J. Fidler, MD, discusses the significance of the IMpower010 clinical trial

Dr. Fidler, Associate Professor, Department of Internal Medicine, Division of Hematology, Oncology & Cell Therapy, Rush Medical College, Rush University ...

video

Mary J. Fidler, MD, provides opinion on the role of nivolumab + ipilimumab in the treatment of NSCLC

Dr. Fidler, Associate Professor, Department of Internal Medicine, Division of Hematology, Oncology & Cell Therapy, Rush Medical College, Rush University ...

video

Roy S. Herbst, MD, PhD, offers his impressions of the ADAURA trial presented at ESMO 2020

Dr. Herbst, Professor of Medicine, Medical Oncology, Professor of Pharmacology, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer ...

video

Alex Spira, MD, PhD, FACP, on the practice-changing potential of the ADAURA study from ESMO 2020

Dr. Spira, Director, Virginia Cancer Specialists (VCS) Research Institute, Co-Chair, US Oncology Thoracic Research Program, Clinical Assistant Professor, Johns Hopkins, ...

video

Alex Spira, MD, PhD, FACP, offers thoughts on the four-year follow-up to the Phase III PACIFIC trial

Dr. Spira, Director, Virginia Cancer Specialists (VCS) Research Institute, Co-Chair, US Oncology Thoracic Research Program, Clinical Assistant Professor, Johns Hopkins, ...

video

Alex Spira, MD, PhD, FACP, shares thoughts on the Phase I CHRYSALIS study presented at ESMO 2020

Dr. Spira, Director, Virginia Cancer Specialists (VCS) Research Institute, Co-Chair, US Oncology Thoracic Research Program, Clinical Assistant Professor, Johns Hopkins, ...

Related Videos

video-image

Mary J. Fidler, MD, on combination lurbinectedin & checkpoint inhibitors in the treatment of SCLC

video-image

Mary J. Fidler, MD, regarding the role of trilaciclib as a supportive care agent for SCLC patients

video-image

Mary J. Fidler, MD, elaborates on what early clinical trials have told us about sotorasib

video-image

Mary J. Fidler, MD, discusses the significance of the IMpower010 clinical trial

video-image

Mary J. Fidler, MD, provides opinion on the role of nivolumab + ipilimumab in the treatment of NSCLC

video-image

Roy S. Herbst, MD, PhD, shares thoughts on the update to Keynote-024 presented at ESMO 2020

video-image

Roy S. Herbst, MD, PhD, elaborates on the design and outcomes of the EMPOWER-lung 1 clinical study

video-image

Roy S. Herbst, MD, PhD, tell us about the PIONeeR study presented at the 2020 ESMO Virtual Congress

video-image

Roy S. Herbst, MD, PhD, offers his impressions of the ADAURA trial presented at ESMO 2020

video-image

Alex Spira, MD, PhD, FACP, on the practice-changing potential of the ADAURA study from ESMO 2020

video-image

Alex Spira, MD, PhD, FACP, offers thoughts on the four-year follow-up to the Phase III PACIFIC trial

video-image

Alex Spira, MD, PhD, FACP, shares thoughts on the Phase I CHRYSALIS study presented at ESMO 2020

video-image

Alex Spira, MD, PhD, FACP, discusses the mechanism of action of amivantamab (JNJ-6372)

video-image

Giuseppe Giaccone, PhD, MD, speculates on next steps in the development of Tedopi (OSE2101)

video-image

Giuseppe Giaccone, PhD, MD, regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCLC

video-image

Pasi A. Jänne, MD, PhD, offers opinion on the next steps in the development of mobocertinib

video-image

Giuseppe Giaccone, PhD, MD, regarding the mechanism of action of Tedopi (OSE2101)

video-image

Pasi A. Jänne, MD, PhD, shares data from ESMO 2020 investigating mobocertinib

video-image

Giuseppe Giaccone, PhD, MD, comments on the incidence of HLA-A2 positive (NSCLC)

video-image

Pasi Jänne, MD, PhD, elaborates on EGFR exon 20 insertions in non-small cell lung cancer

video-image

Charu Aggarwal, MD, MPH, on approach to Checkpoint Inhibitors as therapy in NSCLC Impact of COVID

video-image

Charu Aggarwal, MD, MPH, on how the findings from the FLAURA and ADURA impact EGFR NSCLC management

video-image

Charu Aggarwal, MD, MPH, discusses the role of liquid biopsies in the management of NSCLC

video-image

Charu Aggarwal, MD, MPH, describes her approach to managing an individual with ALK positive NSCLC

video-image

Roy Herbst, MD, PhD, provides thoughts on stereotactic radiation plus TKI therapy regarding NSCLC

video-image

Edward Garon MD, expounds on the new FDA approval of erlotinib + ramuciramab in EGFR positive advanced non-small cell lung cancer (NSCLC)

video-image

Edward Garon, MD, examines the ADAURA clinical study regarding adjuvant treatment in NSCLC

video-image

Edward Garon, MD, examines dual immunotherapy approach in the CITYSCAPE trial

video-image

Edward Garon, MD, discusses length of use when combining I-O with chemotherapy in 1st line NSCLC

video-image

Roy Herbst, MD, PhD, discusses next steps in clinical development of osimertinib in adjuvant NSCLC

video-image

Roy Herbst, MD, PhD, explains the 3-year length of adjuvant treatment strategy in ADAURA

video-image

Roy Herbst, MD, PhD, considers assessing NSCLC patients who recur after completing adjuvant osimertinib(Tagrisso)

video-image

Xiuning Le, MD, PhD, shares impressions of the randomized Phase 2 CITYSCAPE study regarding NSCLC

video-image

Xiuning Le, MD, PhD, describes the ADAURA clinical study as an adjuvant treatment in NSCLC

video-image

Xiuning Le, MD, PhD, considers tepotinib development going forward as a result of the VISION study

video-image

Xiuning Le, MD, PhD, discusses testing for METex14 skipping and validating it in the VISION study

video-image

Xiuning Le, MD, PhD, discusses the mechanism of action for tepotanib and how it targets NSCLC

video-image

Roy Herbst, MD, PhD, shares perspective on the plenary session presentation of the ADAURA study

video-image

Xiuning Le, MD, PhD, discusses goals and results of the VISION study in non-small cell lung cancer

video-image

Yuanbin Chen, MD, explains the impact of the 2nd arm in the CASPIAN study in small cell lung cancer

video-image

Yuanbin Chen, MD, discusses the potential practice changing outcomes of the CASPIAN trial

video-image

Charles Rudin, MD, PhD, shares the take home message regarding Keynote-604 for lung cancer treatment

video-image

Charles Rudin, MD, PhD, discusses the Keynote-604 study and the role of Keytruda in ES-SCLC

video-image

Yuanbin Chen, MD, shares outcomes of the Phase 3 CASPIAN trail investigating Imfinzi (durvalumab) + chemotherapy

video-image

Vivek Subbiah, MD, on the FDA approved product, selpercatanib, for RET-driven lung and thyroid cancers

video-image

Vivek Subbiah, MD, describes solid tumor tests for RET fusion and similarities it may have to other targeted therapy tests

video-image

Charles Rudin, MD, PhD, shares outcomes of the Keynote 604 study investigating the combination of Keytruda and chemotherapy in ES-small cell lung cancer patients

video-image

Vivek Subbiah, MD, on developing targeted therapies for RET fusion + solid tumors and the effectivity

video-image

Vivek Subbiah, MD, describes the incidence of RET fusion + solid tumors amongst cancer patients and when RET-fusion + targeted therapies will be most effective

video-image

Shirish M. Gadgeel MBBS, comments on significant studies in ALK+ NSCLC from ESMO 2019

video-image

Christian Rolfo, MD, PhD, MBA, on the role of liquid biopsy in the treatment of lung cancer

video-image

Shirish M. Gadgeel MBBS, speculates on the future of RET-altered NSCLC

video-image

Christian Rolfo, MD, PhD, MBA, on the development of RET-Fusion in NSCLC

video-image

Shirish M. Gadgeel MBBS, regarding the most exciting data in lung cancer from ESMO 2019

video-image

Geoffrey Oxnard, MD, on the effectiveness of lorlatinib as a frontline agent in ALK+ NSCLC

video-image

Geoffrey Oxnard, MD, explains how genomic markers can guide treatment in PD-L1 positive NSCLC

video-image

Suresh Ramalingam, MD, provides perspective on the PD-L1 and TMB biomarkers in lung cancer

video-image

David Spigel, MD, on how results from the FLAURA study impact treatment selection in lung cancer

video-image

Suresh Ramalingam, MD, offers opinion on optimal sequencing of immunotherapy in NSCLC

video-image

David Spigel, MD, tells us about the results of CheckMate-227 presented at ESMO 2019

video-image

Suresh Ramalingam, MD, on how the FLAURA trial may impact care for EGFR-mutated NSCLC

video-image

David Spigel, MD, on the use of genomic markers like TMB to guide 1st NSCLC treatment

video-image

Geoffrey Oxnard, MD, on the FLAURA study impacting treatment selection in EGFR mutant lung cancer

video-image

Suresh Ramalingam, MD, discusses the results of CheckMate 227 in advanced NSCLC patients

video-image

Suresh Ramalingam, MD, FASCO, shares results from the FLAURA trial presented at ESMO 2019

video-image

Marwan Fakih, MD, discusses the Phase 1 trial evaluating AMG 510 in CRC and NSCLC

video-image

Sandip Patel, MD, on treatment in the 2nd line setting following PD-L1 targeting agents

video-image

Sandip Patel, MD, speculates on the impact of the RELAY trial presented at ASCO 2019

video-image

Shirish Madhav Gadgeel, MBBS, on treating patients who have already received PD-L1 targeting agents

video-image

Shirish Madhav Gadgeel, MBBS, offers opinion on the results of the RELAY trial from ASCO 2019

video-image

Lowell L. Hart, MD, FACP, regarding recent data investigating trilaciclib in SCLC

video-image

Sandip Patel, MD, on treating non-squamous NSCLC patients expressing high levels of PD-L1

video-image

Kristin Higgins, MD, offers opinion on the PACIFIC study in non-small cell lung cancer

video-image

Shirish Madhav Gadgeel, MBBS, on treating non-squamous NSCLC patients expressing high PD-L1

video-image

Marwan G. Fakih, MD, on why AMG 510 seems promising in colorectal and lung cancers

video-image

Sandip Patel, MD, comments on the top stories in lung cancer from ASCO 2019

video-image

Kristin Higgins, MD, shares her interpretation of the PACIFIC study in unresectable NSCLC

video-image

Shirish Madhav Gadgeel, MBBS, regarding the top stories in lung cancer from ASCO 2019

video-image

Naiyer Rizvi, MD, speculates on the future of drug development in NSCLC

video-image

Naiyer Rizvi, MD, offers thoughts on the role of blood TMB vs. tissue TMB

video-image

Naiyer Rizvi, MD, describes the role of PD-L1 & TMB biomarkers in the treatment of lung cancer

video-image

Naiyer Rizvi, MD, tells us about the results of Keynote-001 in NSCLC

video-image

Ravi Salgia, MD, PhD, considers the unmet medical needs in the treatment of NSCLC

video-image

Ravi Salgia, MD, PhD, on treatment in the 2nd line setting after 1st line PD-L1 targeting agents

video-image

Ravi Salgia, MD, PhD, on the ideal patient to receive Alimta plus Keytruda based on Keynote-189

video-image

Ravi Salgia, MD, PhD, on treating non-squamous, NSCLC patients with high levels of PD-L1

video-image

Ravi Salgia, MD, PhD, offers strategies for identifying PD-L1 status

video-image

Ravi Salgia, MD, PhD, outlines some of the molecular tests utilized prior to treating advanced NSCLC

video-image

Ravi Salgia, MD, PhD, comments on germline mutations & the impact on NSCLC patients

video-image

Edward B. Garon, MD, on the implications of Keynote-189

video-image

Edward B. Garon, MD, elaborates on the role of PD-L1 in the management of lung cancer

video-image

Edward B. Garon, MD, considers the implications of Keynote-001 in advanced NSCLC

video-image

Pasi A. Jänne, MD, PhD, regarding the unmet medical needs in the treatment of NSCLC

video-image

Pasi A. Jänne, MD, PhD, discusses some of the challenges in managing NSCLC

video-image

Martin E. Gutierrez, MD, discusses some of the top challenges in managing NSCLC

video-image

Pasi A. Jänne, MD, PhD, on treating patients in the 2nd line setting after 1st line Keytruda

video-image

Martin E. Gutierrez, MD, on 2nd line treatment options following 1st line PD-L1 targeting agents

video-image

Pasi A. Jänne, MD, PhD, elaborates on outcomes from the RELAY trial

video-image

Martin E. Gutierrez, MD, discusses the implications of the RELAY trial from ASCO 2019

video-image

Pasi A. Jänne, MD, PhD, on treating non-squamous NSCLC patients expressing high levels of PD-L1

video-image

Pasi A. Jänne, MD, PhD, on molecular testing prior to the treatment of advanced NSCLC

video-image

Martin E. Gutierrez, MD, on treating non-squamous NSCLC patients expressing high levels of PD-L1

video-image

Pasi A. Jänne, MD, PhD, on the study of U3-1402 in EGFR mutant NSCLC presented at ASCO 2019

video-image

Martin E. Gutierrez, MD, on the role of clinico-genomic data sharing in lung cancer treatment

video-image

Pasi A. Jänne, MD, PhD, on advances in the treatment of lung cancer being presented at ASCO 2019

video-image

Ravi Salgia, MD, PhD, offers opinion on the top challenges in managing NSCLC

video-image

Melissa Johnson, MD, shares her thoughts on biomarker development in NSCLC

video-image

Melissa Johnson, MD, speculates on exciting developments in the treatment of NSCLC

video-image

Melissa Johnson, MD, considers the recent data investigating atezolizumab in SCLC

video-image

Alexander Spira, MD, PhD, FACP, tells us the latest thinking regarding the PD-L1 biomarker

video-image

Alexander Spira, MD, PhD, FACP, on managing lung cancer patients in a community setting

video-image

Alexander Spira, MD, PhD, FACP, on the recent approval of atezolizumab in SCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on pemetrexed maintenance therapy

video-image

Sai-Hong Ignatius Ou, MD, PhD, discusses key takeaways from the IMpower150 study at ASCO 2018

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, regarding combo chemotherapy & immunotherapy in 1st line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on testing for PD-L1 expression in NSCLC

video-image

Benjamin Philip Levy, MD, on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Benjamin Philip Levy, MD, on maintenance therapy following carboplatin, pemetrexed & pembrolizumab

video-image

Benjamin Philip Levy, MD, comments on the IMpower150 clinical trial in NSCLC

video-image

Benjamin Philip Levy, MD, on options for NSCLC patients who progress on 1st line I-O & chemotherapy

video-image

Benjamin Philip Levy, MD, regarding combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Benjamin Philip Levy, MD, discusses the practice-changing outcomes from Keynote 189

video-image

Benjamin Philip Levy, MD, offers opinion on testing for PD-L1 expression in NSCLC

video-image

Howard (Jack) West, MD, regarding Tumor Mutation Burden (TMB) as a biomarker for NSCLC patients

video-image

Howard (Jack) West, MD, on maintenance therapy after carboplatin, pemetrexed & pembrolizimab

video-image

Howard (Jack) West, MD, discusses key takeaways from the IMpower150 study in NSCLC

video-image

Howard (Jack) West, MD, on treatment options for patients who progress on I-O & chemotherapy

video-image

Howard (Jack) West, MD, regarding the combination of immunotherapy & chemotherapy in NSCLC

video-image

Howard (Jack) West, MD, regarding PDL-1 expression and NSCLC

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, considers predictive biomarkers in NSCLC

video-image

Mohammad Jahanzeb, MD, FACP, discusses the significance of Keynote 42 from ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Mohammad Jahanzeb, MD, FACP, on the results of Keynote 189, PDL-1 expression and patient selection

video-image

Edgardo S. Santos, MD, FACP, on the benefits of combination docetaxel + ramucirumab

video-image

Edgardo S. Santos, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Edgardo S. Santos, MD, FACP, on the outcomes of Keynote 189 in metastatic NSCLC

video-image

Edgardo S. Santos, MD, FACP, discusses exciting developments out of ASCO 2018

video-image

Roy S. Herbst, MD, PhD, discusses the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

Roy S. Herbst, MD, PhD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

Roy S. Herbst, MD, PhD, on if patient selection will change as a result of Keynote 42

video-image

Roy S. Herbst, MD, PhD, on pemextrexed maintenance treatment

video-image

Roy S. Herbst, MD, PhD, shares what's exciting here at ASCO 2018

video-image

Roy S. Herbst, MD, PhD, on if Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

Joan Schiller, MD, regarding Keynote trials from ASCO 2018 & the influence on choice of therapy

video-image

Joan Schiller, MD, considers the validity of Tumor Mutation Burden (TMB) as a biomarker

video-image

Joan Schiller, MD, on the impact of Keynotes 189 & 42 on drug sequencing regimens

video-image

Joan Schiller, MD, regarding the results of Keynote 42 presented at the 2018 ASCO Annual Meeting

video-image

Joan Schiller, MD, considers the continuation of pemetrexed maintenance

video-image

Joan Schiller, MD, offers her opinion on Keynote 189 & PDL-1 expression and patient selection

video-image

David R. Gandara, MD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

David R. Gandara, MD, on what will change about patient selection as a result of Keynote 42

video-image

David R. Gandara, MD, on continuing pemextrexed maintenance

video-image

David R. Gandara, MD, on whether Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

David R. Gandara, MD, shares the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

David R. Gandara, MD, discusses exciting new developments in lung cancer here at ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, discusses the impact of Keynote 189 & 42 on drug sequencing regimens

video-image

Melissa Johnson, MD, on how Next Generation Sequencing is relevant to the treatment of NSCLC

video-image

Melissa Johnson, MD, discusses combinations and the treatment of lung cancer

video-image

Melissa Johnson, MD, on lung cancer patients that have a PD-L1 expression that is less than 1%

video-image

Melissa Johnson, MD, on stratifying newly diagnosed lung cancer patients with the PD-L1 biomarker

video-image

Melissa Johnson, MD, clarifies how physicians should use the PD-L1 biomarker

video-image

Mary Jo Fidler, MD, FASCO, considers the biomarker challenges when treating SCLC

video-image

Mary Jo Fidler, MD, FASCO, comments on the outlook for immunotherapy combinations in SCLC

video-image

Mary Jo Fidler, MD, FASCO, offers opinion on integrating immunotherapies into treatment of SCLC

video-image

George Simon, MD, FACP, FCCP, regarding the most impactful clinical studies on lung cancer at ASCO

video-image

Edward Kim, MD, provides insight on how to use the PD-L1 biomarker to direct therapy

video-image

Edward Kim, MD, describes how immunotherapy combinations will be used in the near future

video-image

Edward Kim, MD, comments on gefitinib versus vinorelbine-cisplatin as adjuvant treatment in NSCLC

video-image

Edward Kim, MD, on anti-PD-L1/PD-1 combination therapies in treatment of lung cancer

video-image

Edward Kim, MD, offers his opinion on the biggest news in lung cancer before and during ASCO 2017

video-image

Phil Bonomi, MD, on immunotherapy for treatment of SCLC and mesothelioma

video-image

Phil Bonomi, MD, offers opinion on whether MET inhibitors are effective in metastatic NSCLC

video-image

Jack West, MD, shares his outlook on IDO inhibitors for treatment of lung cancer

video-image

Jack West, MD, on what we know about durvalumab in treatment of stage 3 NSCLC

video-image

Jack West, MD, on anti-PD-L1/PD-1 therapy in combination with chemotherapy & targeted therapies

video-image

Lyudmila Bazhenova, MD, on treating ALK+ lung cancer patients with ALK inhibitors

video-image

Jack West, MD, discusses PD-L1/PD-1 therapy in lung cancer treatment algorithms

video-image

Julie Brahmer, MD, discusses considerations when choosing between immunotherapy and chemotherapy

video-image

Julie Brahmer, MD, talks about the potential impact of immunotherapy in 1st line NSCLC

video-image

David Ettinger, MD, talks about impact of immunotherapy in 1st line metastatic NSCLC patients

video-image

David Gandara, MD, discusses considerations when choosing between immunotherapy and chemotherapy

video-image

David Gandara, MD, discusses the positioning of Cyramza post platinum therapy in NSCLC patients

video-image

David Gandara, MD, discusses PD-L1 expression and selecting the appropriate agent in NSCLC patients

video-image

David Ettinger, MD, provides practical advice related to PD-L1 testing in metastatic NSCLC patients

video-image

Julie Brahmer, MD, provides practical advice related to PD-L1 testing in NSCLC patients

video-image

Julie Brahmer, MD, on the importance of overall cost of therapy

video-image

Julie Brahmer, MD, on the level of PD-L1 expression in selecting the appropriate agent in NSCLC

video-image

David Ettinger, MD, on cost of therapy when choosing agents for late stage lung cancer patients

video-image

David Ettinger, MD, on choosing between immunotherapy and chemotherapy in metastatic NSCLC patients

video-image

David Ettinger, MD, on the positioning of ramucirumab (Cyramza) for NSCLC

video-image

David Ettinger, MD, talks about levels of PD-L1 expression and agent selection

video-image

David Gandara, MD, talks about the potential impact of immunotherapy in 1st line NSCLC

video-image

Julie Brahmer, MD, on positioning of ramucirumab (Cyramza) post-platinum therapy in NSCLC patients

video-image

David Gandara, MD, discusses pembrolizumab vs docetaxel for previously treated NSCLC patients

video-image

Phil Bonomi, MD, on importance of checkpoint inhibitors in first-line NSCLC setting

video-image

Phil Bonomi, MD, talks about the evolving role of targeted agents in 2nd line NSCLC and beyond

video-image

Phil Bonomi, MD, discusses costs of new lung cancer therapies relative to duration of therapy

video-image

Mohammad Jahanzeb, MD, FACP speaks about testing for PD-L1 in the first-line NSCLC setting